PharmAust (ASX:PAA) posted positive preliminary results in experiments aimed at inhibiting the virus that causes COVID-19. PharmAust, which traditionally is focused on repurposing existing drugs for cancer therapy, is...
iBio (NYSE AMERICAN:IBIO) initiated preclinical immunization studies for its second COVID-19 vaccine platform with the potential for rapid manufacturing scale-up at its FastPharming System. The new subunit vaccine, IBIO...
Ocugen (NASDAQ:OCGN) is discontinuing the Phase 3 trial of OCU300 for ocular graft vs. host disease (oGVHD) based on results of a pre-planned interim sample size analysis conducted by an independent data monitoring...
Menlo Therapeutics’ (NASDAQ:MNLO) ZILXI received FDA approval for the treatment of inflammatory lesions of rosacea in adults. The company noted that ZILXI, a minocycline topical foam, is the first minocycline product of...
Myovant Sciences’ (NASDAQ:MYOV) reported additional positive results from its Phase 3 HERO study of once-daily, oral relugolix in men with advanced prostate cancer. In the primary endpoint responder analysis, 97% of men...
AVEO Oncology (NASDAQ:AVEO) reported positive final overall survival results from its Phase 3 TIVO-3 trial comparing tivozanib to sorafenib in third- and fourth-line renal cell carcinoma (RCC). The trial met the...
Closely-held Repare Therapeutics inked an exclusive, worldwide research collaboration with Bristol Myers Squibb (NYSE:BMY). Under the accord, the companies will leverage Repare’s CRISPR-enabled genome-wide synthetic...
Cardiff Oncology’s (NASDAQ:CRDF) onvansertib received FDA fast track designation for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). The company is currently assessing...
Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported positive topline data from its Phase 2 trial of Zygel for the treatment of autism spectrum disorder (ASD). Zygel is a cannabidiol-based gel that provides controlled...
The FDA has granted IntelGenx Technologies’ (TSXV:IGX; OTCQX:IGXT) request for a Type A meeting to discuss the company’s RIZAPORT VersaFilm program. The meeting is scheduled for June 10, 2020. On March...